Maha Kosa

Viracept (Nelfinavir Mesylate, AG1343):  A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease

Stephen W. Kaldor, Vincent J. Kalish, Jay F. Davies et al. · Journal of Medicinal Chemistry · 1997 · 620 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P₁ Lactam Moieties as <scp>l</scp>-Glutamine Replacements

Peter S. Dragovich, Thomas J. Prins, Ru Zhou et al. · Journal of Medicinal Chemistry · 1999 · 189 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +16

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 6. Structure−Activity Studies of Orally Bioavailable, 2-Pyridone-Containing Peptidomimetics

Peter S. Dragovich, Thomas J. Prins, Ru Zhou et al. · Journal of Medicinal Chemistry · 2002 · 142 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics

Peter S. Dragovich, Thomas J. Prins, Ru Zhou et al. · Journal of Medicinal Chemistry · 2003 · 115 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies

S. E. Webber, Charlotte A. Bartlett, Theodore J. Boritzki et al. · Cancer Chemotherapy and Pharmacology · 1996 · 91 citations

Life Sciences, Medicinal Chemistry, Molecular Biology +5